Swedish Orphan Biovitrum Stock (OTC: SWOBY)

Latest news for Swedish Orphan Biovitrum (OTC:SWOBY) Stock

Swedish Orphan Biovitrum, or Sobi, focuses on rare diseases, primarily in hematology and immunology. Biovitrum started with experience in studying recombinant proteins such as hemophilia factors, and partnered with Syntonix (now part of Sanofi) on long-acting hemophilia factor replacement programs in 2006. Biovitrum acquired Orfadin and a partnered product business with the acquisition of Swedish Orphan. Sobi launched hemophilia products Alprolix and Eloctate in Europe in 2016. Sobi has since been building its immunology pipeline (rare disease drug Gamifant, US rights to RSV antibodies Synagis and Beyfortus, gout drug SEL-212, complement drug Aspaveli) and hematology pipeline outside of hemophilia (thrombocytopenia drug Doptelet, blood cancer drug Zynlonta, myelofibrosis drug Vonjo).

Genetic,Research,And,Biotech,Science,Concept.,Human,Biology,And,Pharmaceutical

Biotech

Equities

News

Health Care

Movers

Trading Ideas

General

APLS

BIOVF

SWOBY

Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary endpoints, showing proteinuria and kidney inflammation reductions.

Apellis Pharmaceuticals&#39; Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases

SWEDISH ORPHAN BIO U/ADR by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

Conglomerate Berkshire Hathaway Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BRK#NYSE">BRK</a>) became the 10th public company to surpass the $1 trillion market capitalization milestone on Wednesday, further reshaping the dynamic leaderboard of the<a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world"> most valuable company in the world.</a>
What Happened: Under the <a href="https://www.benzinga.com/general/movers-shakers/21/08/17298128/warren-buffett-turns-91-a-highlight-for-each-decade-of-his-life-1">long-time leadership</a> of Warren Buffett, Berkshire Hathaway has reached the $1 trillion mark, with shares up 28% year-to-date in 2024.
The stock is one of eight companies to currently be valued at $1 trillion or more. Berkshire Hathaway is also the first U.S. based non-technology company to pass the milestone.
The current list of $1 trillion valued public companies is:
<ul>
<li>Apple: $3.47 trillion</li>
<li>Nvidia: $3.12 trillion</li>
<li>Microsoft: $3.06 trillion</li>
<li>Alphabet: $2.02 trillion</li>
<li>Amazon.com: $1.80 trillion</li>
<li>Saudi Aramco: $1.79 trillion</li>
<li>Meta Platforms: $1.30 trillion</li>
<li>Berkshire Hathaway: $1.03 trillion</li>
</ul>
Previous members of the club include Petro China and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
"As Berkshire Hathaway approaches a $1 trillion market cap, which company will be the next to reach this milestone?" Benzinga asked earlier this week.
Here are the results and the market capitalizations at the time of the poll:
<ul>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>): 43%</li>
<li>Taiwan Semiconductor Manufacturing (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSM#NYSE">TSM</a>): 25%</li>
<li>Tesla: 19%</li>
<li>Broadcom Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>): 11%</li>
<li>Walmart Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>): 3%</li>
</ul>
At the time of writing, Taiwan Semiconductor and Eli Lilly are closest to hitting the milestone, with both companies worth over $800 billion. Eli Lilly won the poll with a near majority of the five selections. Taiwan Semiconductor Manufacturing ranked second with a quarter of the vote.
Broadcom, which has the next highest market capitalization at $743 billion, ranked fourth. Tesla ranked third, despite having a lower market capitalization of $665 billion. Walmart, which has a market capitalization of $610 billion, finished fifth in the poll.
Did You Know?
<ul>
<li>Congress Is Making Huge Investments. <a href="https://www.benzinga.com/gov-trades/?utm_source=BZprocontent082824">Get Tips On What They Bought And Sold Ahead Of The 2024 Election With Our Easy-to-Use Tool</a></li>
</ul>
Why It's Important: While it seems like Nvidia has been one of the most valuable companies in the world for some time, the company passed the $1 trillion market cap milestone just 15 months ago,<a href="https://www.benzinga.com/news/23/05/32630114/nvidia-becomes-ninth-company-to-hit-1-trillion-market-cap-who-could-be-next-to-join-elusive-club"> back in May 2023,</a> and briefly became the most valuable company in the world<a href="https://www.benzinga.com/news/24/06/39386946/microsoft-apple-step-aside-nvidia-is-now-the-most-valuable-public-company-in-the-world"> earlier this year.</a>
Meta Platforms, which was a past member of the $1 trillion market capitalization before falling out, re-joined the club earlier this year.
Last May, when Nvidia joined the club, Benzinga asked its social media followers which stock would be next to join or re-join the $1 trillion market capitalization club.
Tesla was <a href="https://www.benzinga.com/news/23/06/32698111/nvidia-recently-hit-a-1-trillion-market-cap-which-stock-is-next-to-join-club-heres-what-benzinga-use">the overwhelming favorite </a>on X at 53.8% of the vote. Ranking second was Taiwan Semiconductor. While neither of those companies has hit the $1 trillion market cap level since then, the third and fourth place finishers in Meta at 15% and Berkshire at 12.9% are now both members.
This just goes to show that the market can be unpredictable.
Berkshire Hathaway has posted impressive gains over the years under Buffett's leadership, and the company&#8217;s ownership of key brands alongside a stock portfolio that includes Apple and other blue chip stocks.
That could be why it's no surprise that Benzinga readers recently selected Buffett as the person <a href="https://www.benzinga.com/top-stories/24/08/40423891/buffett-musk-wood-cuban-or-ackman-who-do-investors-trust-most-with-life-savings-poll-shows-it-isnt-e">they would trust </a>most with investing their life savings in a poll. Buffett was selected with an overwhelming 58% of the vote over the likes of Ray Dalio, Cathie Wood, Elon Musk, Bill Ackman, Mark Cuban and Jamie Dimon.
Berkshire Hathaway shares are up 31% in the past year and up 129% over the last five years.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/08/40531771/benzingas-stock-whisper-index-5-stocks-investors-secretly-monitor-but-dont-talk-about-yet">Benzinga&#8217;s &#8216;Stock Whisper&#8217; Index: 5 Stocks Investors Secretly Monitor But Don&#8217;t Talk About Yet</a></li>
</ul>
The study was conducted by Benzinga on Aug. 26 through Aug. 27, 2024, and included the responses of a diverse population of adults 18 or older. Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from 101 adults.
Image created using artificial intelligence via Midjourney.

Exclusives

AVGO

TSLA

Warren Buffett's Berkshire Hathaway Breaks $1 Trillion: Poll Points To Big Pharma, Not Tech, As Next Contender

DA Davidson analyst Michael Baker maintains Citi Trends (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTRN#NASDAQ">CTRN</a>) with a Buy and lowers the price target from $33 to $20.

Price Target

Analyst Ratings

CTRN

DA Davidson Maintains Buy on Citi Trends, Lowers Price Target to $20

UTime Shares Halted On Circuit Breaker To The Downside, Stock Now Down -83%

Keefe, Bruyette &amp; Woods analyst Damon Delmonte maintains First Merchants (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRME#NASDAQ">FRME</a>) with a Outperform and maintains $45 price target.

FRME

Keefe, Bruyette & Woods Maintains Outperform on First Merchants, Maintains $45 Price Target

Keefe, Bruyette &amp; Woods analyst Wood Lay maintains CrossFirst Bankshares (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CFB#NASDAQ">CFB</a>) with a Outperform and maintains $20 price target.

Keefe, Bruyette & Woods Maintains Outperform on CrossFirst Bankshares, Maintains $20 Price Target

Nvidia Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) is set to report its highly anticipated earnings on Aug. 28, and the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40597015/will-nvidia-continue-to-deliver-investors-sweat-over-hyped-up-expectations-and-pote">stakes couldn't be higher.</a>
As the undisputed leader in the AI revolution, Nvidia&#8217;s results will be a critical indicator for the broader market, particularly for those invested in semiconductor and technology sectors.
This highly followed market event offers both risk and opportunity. For traders seeking to capitalize on Nvidia's earnings without the direct exposure to single-stock volatility, ETFs with substantial Nvidia holdings present an appealing alternative. 
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40596306/market-eyes-305b-shift-in-nvidias-market-cap-as-options-pricing-forecasts-9-8-post-">Market Eyes $305B Shift In Nvidia&#8217;s Market Cap As Options Pricing Forecasts 9.8% Post-Earnings Move: &#8216;A Lot Of That Insurance Is FOMO&#8217;</a>
<h3 class="wp-block-heading">Nvidia Earnings Expectations: A High Bar Set</h3>
Wall Street has set an ambitious target for Nvidia this quarter, with revenue expected to hit $28.74 billion — a staggering 17% increase from the previous quarter and an eye-popping 156% jump from the same quarter last year. 
Earnings per share (EPS) are forecasted to rise to 65 cents, up from 56 cents in the prior quarter and 21 cents in the same period last year.
Goldman Sachs&#8217; semiconductor analyst, Toshiya Hari, is bullish on Nvidia&#8217;s prospects, predicting the company will surpass these already lofty expectations. 
&#8220;We believe customer demand across the large Cloud Service Providers and enterprises is strong, and Nvidia&#8217;s robust competitive position in AI/accelerated computing remains intact,&#8221; Hari stated in a note published this month. 
The driving force behind this optimism? Data Center revenues and strong operating leverage. Hari highlights three key areas: robust demand for the H100 GPUs, the launch of volume shipments of the H200, and the ramp-up of Nvidia&#8217;s Ethernet-based networking product, Spectrum-X. These factors could fuel a significant earnings beat, potentially leading to upward revisions in EPS.
Shares of the AI tech giant are up 159% year to date, after surging by 239% in 2023. 
<h3 class="wp-block-heading">Historical Volatility: A Look At Past Nvidia Earnings</h3>
Nvidia&#8217;s stock has a history of sharp rallies post-earnings, with an average one-day boost of 9% over the past eight quarters and 7.1% over the last four.
A Goldman Sachs analysis identified the VanEck Semiconductor ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMH#NASDAQ">SMH</a>) as having the highest average post-earnings move (3.4%) following Nvidia's past eight earnings releases. 
It was followed by the iShares Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SOXX#NYSE">SOXX</a>) at 2.9% and the ARK Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>) at 2.4%.
<h3 class="wp-block-heading">Top 10 ETFs With Nvidia Exposure</h3>
For traders looking to gain exposure to Nvidia's potential earnings-driven rally, here are 10 ETFs with the largest holdings in the stock:
<figure class="wp-block-table is-style-stripes"> 
<table>
<thead>
<tr>
<th>ETF Name</th>
<th>Nvidia Weight %</th>
<th>YTD Performance (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ProShares Ultra Semiconductors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USD#NYSE">USD</a>)</td>
<td>30.69%</td>
<td>136%</td>
</tr>
<tr>
<td>Strive U.S. Semiconductor ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOC#NYSE">SHOC</a>)</td>
<td>29.54%</td>
<td>19.2%</td>
</tr>
<tr>
<td>Simplify Volt RoboCar Disruption (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VCAR#NYSE">VCAR</a>)</td>
<td>22.83%</td>
<td>12.7%</td>
</tr>
<tr>
<td>VanEck Semiconductor ETF </td>
<td>21.95%</td>
<td>41.3%</td>
</tr>
<tr>
<td>The Technology Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>)</td>
<td>21.29%</td>
<td>16.7%</td>
</tr>
<tr>
<td>Grizzle Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DARP#NYSE">DARP</a>)</td>
<td>20.32%</td>
<td>13.9%</td>
</tr>
<tr>
<td>Franklin Focused Growth ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FFOG#NYSE">FFOG</a>)</td>
<td>18.07%</td>
<td>26.4%</td>
</tr>
<tr>
<td>iShares Global Tech ETF (IXN)</td>
<td>17.55%</td>
<td>21.6%</td>
</tr>
<tr>
<td>iShares ESG Advanced MSCI USA ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USXF#NYSE">USXF</a>)</td>
<td>16.05%</td>
<td>22.4%</td>
</tr>
<tr>
<td>SoFi Select 500 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SFY#NYSE">SFY</a>)</td>
<td>15.96%</td>
<td>20.5%</td>
</tr>
</tbody>
</table>
</figure>
Now Read:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40600345/big-tech-is-your-flight-to-safety-and-your-flight-to-growth-says-expert-ahead-of-nv">&#8216;Big Tech Is Your Flight To Safety And Your Flight To Growth,&#8217; Says Expert Ahead Of Nvidia Earnings</a></li>
</ul>

Large Cap

Sector ETFs

Broad U.S. Equity ETFs

Tech

ETFs

ARKK

DARP

Franklin Templeton ETF Trust Franklin Focused Growth ETF

FFOG

NVDA

EA Series Trust Strive U.S. Semiconductor ETF

SHOC

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

USXF

Simplify Volt RoboCar Disruption and Tech ETF

VCAR

10 ETFs Poised For Wild Swings Following Nvidia Earnings

Polestar Automotive Holding UK PLC&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) shares are trading lower on Wednesday. The Swedish electric performance car brand disclosed that Michael Lohscheller will become <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/b40593214/polestar-announces-leadership-change-michael-lohscheller-appointed-ceo" rel="noreferrer noopener">CEO effective October 1, 2024</a>.
Lohscheller will succeed Thomas Ingenlath, who is stepping down after successfully positioning the brand for its next phase.
Michael Lohscheller has formerly worked as the CEO of Opel, VinFast, and Nikola. Polestar aims to expand its global presence and strengthen its position in the premium electric vehicle market.
Winfried Vahland, Polestar&#8217;s incoming Chairman, said, &#8220;Polestar has experienced an exceptional start-up phase and with a broader model line-up, Michael Lohscheller is the ideal leader to guide Polestar into its next chapter.&#8221;
&#8220;His deep industry knowledge, especially in driving operational excellence, developing a coherent product strategy and strengthening the global market presence will be instrumental in the next chapter of Polestar&#8217;s growth.&#8221;
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, PSNY stock has lost over&nbsp;70%&nbsp;in the last 12 months year. Investors can gain exposure to the stock via&nbsp;SPDR S&amp;P Kensho Smart Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAIL#NYSE">HAIL</a>).
Price Action: PSNY shares are down 14.6% at $0.9651 at the last check Wednesday.
Photo by Jeppe Gustafsson on Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40387487/polestar-starts-production-in-us-to-avoid-high-tariffs-imposed-on-china-made-evs" target="_blank" rel="noreferrer noopener">Polestar Starts Production In US To Avoid High Tariffs Imposed On China-Made EVs</a></li>
</ul>
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Don&#8217;t miss the opportunity to dominate in a volatile market at the&nbsp;<a target="_blank" href="https://www.benzinga.com/events/small-cap/global-small-cap-conference-2024/" rel="noreferrer noopener">Benzinga SmallCAP Conference</a>&nbsp;on Oct. 9-10 at the Chicago Marriott Downtown Magnificent Mile. Get exclusive access to CEO presentations, 1:1 meetings with investors, and valuable insights from top financial experts. Whether you&#8217;re a trader, entrepreneur, or investor, this event offers unparalleled opportunities to grow your portfolio and network with industry leaders. Secure your spot and get your tickets today!

Small Cap

Management

HAIL

PSNY

Why Is Polestar Automotive Stock Diving Today?

Greenway Greenhouse Cannabis Corporation (CSE:<a class="ticker" href="https://www.benzinga.com/stock/GWAY#CSE">GWAY</a>) (OTCQB:<a class="ticker" href="https://www.benzinga.com/stock/GWAYF#OTCQB">GWAYF</a>), a Canadian cannabis cultivator reported its interim financial statements on Wednesday for the first quarter ended June 30, 2024.
The Ontario-based company said it has achieved its highest net revenue and adjusted EBITDA results to date. The company also achieved positive net cash flow provided by operating activities, and the highest amount of cannabis sold in a quarter to date.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/events/cannabis-conference/"><img loading="lazy" decoding="async" width="970" height="250" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/08/28101244/ccc-oct-24-banner__1_-22.gif" alt="" class="wp-image-518554" /></a></figure>
"This performance reflects our focus and commitment to producing quality cannabis, and finding the best partners and pathways to bring it to consumers,&#8221; said CEO Jamie D&#8217;Alimonte. &#8220;We achieved this while still keeping our cost of production low, and our yields high. This combination is what we believe separates us from other public cannabis companies in Canada.&#8221;
Read Also: <a href="https://www.benzinga.com/markets/cannabis/24/07/40047803/greenways-full-year-net-loss-widens-sees-rebound-in-q4-as-revenue-increases-9-yoy">Greenway&#8217;s Full-Year Net Loss Widens, Sees Rebound In Q4 As Revenue Increases 9% YoY</a>
<ul>
<li>Get Benzinga's exclusive analysis and the top news about the cannabis industry and markets daily in your inbox for free. Subscribe to our newsletter <a href="https://newsletteremail.benzinga.com/subscribe" target="_blank" rel="noreferrer noopener">here</a>. If you're serious about the business, you can't afford to miss out.</li>
</ul>
<h3 class="wp-block-heading">Q1 2024 Financial Highlights</h3>
<ul>
<li>Net revenue totaled CA$2.4 million ($1.8 million) in the quarter, compared to CA$1.8 million in the prior year's period, representing a 104% year-over-year increase.</li>
<li>Cost of sales comprised of CA$1.5 million of cash expenses and CA$483,800 of amortization expense resulting in a total gross margin before inventory impairment and fair value adjustments of 14%.</li>
<li>Gross profit totaled CA$342,922, compared to CA$260,884 in the prior year's period.</li>
<li>Operating loss amounted to CA$272,429, representing an improvement from an operating loss of CA$929,796 in the first quarter of last year.</li>
<li>Loss and comprehensive loss totaled CA$541,478, an improvement from CA$1.1 million loss in the prior year's period.</li>
<li>Adjusted EBITDA&nbsp;came in positive at&nbsp;CA$316,431, compared to CA$16,408 in the first quarter of fiscal 2013.</li>
</ul>
&#8220;This is the first full quarter that includes sales of our branded products, and I&#8217;m pleased to share that our MillRite pre-rolls ranked as the second highest-selling in Ontario within their size category,&#8221; D&#8217;Alimonte added. &#8220;Additionally, we recently completed our first harvest intended for international markets, the next step in distributing Greenway cannabis globally.&#8221;
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/cannabis/23/10/35222387/canadian-cannabis-cultivator-ramps-up-distribution-channels-via-new-partnership">Canadian Cannabis Cultivator Ramps Up Distribution Channels Via New Partnership</a></li>
</ul>

Cannabis

Earnings

CSE:GWAY

GWAYF

Greenway Cannabis Co. Doubles Q1 Net Revenue YoY, Highest Adjusted EBITDA Results To Date

<ul>
<li>Nvidia is poised for a dramatic shift in market value, with a potential swing of $300 billion in its market cap.</li>
<li>Nvidia&#39;s current valuation is approximately $3.14 trillion.</li>
<li>Bullish signs in Nvidia&#39;s stock suggest a possible move towards $150.</li>
</ul>
As NVIDIA Corp (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvda#NASDAQ">NVDA</a>) prepares for its upcoming earnings report, the tech giant stands on the brink of a potentially historic change in its market value. Industry analysts, using options pricing data, predict a possible swing of up to $300 billion in Nvidia&#39;s market capitalization.
This figure not only reflects the company&#39;s large valuation, around $3.14 trillion but also highlights the significant impact such a change could have, overshadowing the market caps of most S&amp;P 500 companies.
The stakes are especially high now. Market sensitivities are elevated, with options traders anticipating a 9.8% stock price fluctuation after the earnings announcement. This is significantly higher than what&#39;s been typical over the past three years.
The increased volatility expectation highlights investors&#39; strong focus on Nvidia. The company has driven about 25% of the S&amp;P 500&#39;s gains this year, underscoring its impact on the broader market.
The anticipated earnings per share of $0.57 will be announced after market close this Wednesday, potentially driving expected fluctuations.
Nvidia&rsquo;s recent market performance adds complexity to the story. The stock has jumped 40% from this month&rsquo;s lows, boosting investor confidence. This rebound is part of a larger upward trend, with a 157% gain year-to-date, including a 9% increase in August.
Historically, Nvidia has shown strong recovery ability, bouncing back from sharp declines, as seen in the recent rally. This resilience is fueling the current bullish momentum, putting the stock close to previous record highs if it gains 10%.
However, navigating the stock market, especially with high-stakes earnings reports, requires nuance. A positive earnings surprise doesn&#39;t automatically lead to a stock price increase, as broader market dynamics and investor sentiment can separate financial results from stock performance.
<img alt="2024-08-28_15-26-20.jpg" src="https://www.benzinga.com/files/u517520/2024-08-28_15-26-20.jpg" style="height:308px; width:624px" />
This unpredictability makes the upcoming earnings report crucial. Adding complexity is Nvidia&#39;s stock movement within a significant range of $90 to $140.
Signs of bullish momentum in this zone suggest the possibility of a breakout. If the stock surpasses the $140 mark, it could quickly target the next resistance level at $150, paving the way for further gains.
After the closing bell on Wednesday, August 27, the stock closed at $128.30, trading down by 1.52%.
This article is from an unpaid external contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.

Nvidia's Next Earnings Report Could Swing Its Market Cap By $300 Billion And Increase The S&P 500 Gains

Wrapped Bitcoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WBTC</a>) price has decreased 4.21% over the past 24 hours to $59,121.00. This is contrary to the coins performance over the past week where it has experienced an up-trend of 1.0%, moving from $59,293.16 to its current price.
The chart below compares the price movement and volatility for Wrapped Bitcoin over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.
<img src="https://www.benzinga.com/files/images/story/2024/1724857427_0.png" alt="price_chart" />
The trading volume for the coin has tumbled 8.0% over the past week while the circulating supply of the coin has risen 0.19%. This brings the circulating supply to 153 thousand, which makes up an estimated 100.0% of its max supply of 153 thousand. According to our data, the current market cap ranking for WBTC is #15 at $9.07 billion.
<img src="https://www.benzinga.com/files/images/story/2024/1724857427_1.png" alt="supply_and_vol" />
<a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$WBTC

Wrapped Bitcoin Decreases More Than 4% Within 24 hours

Disclosed on August 27, ROBERT STEPHENSON, Chief Financial Officer at Omega Healthcare Invts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OHI#NYSE">OHI</a>), executed a substantial insider sell as per the latest SEC filing.
What Happened: STEPHENSON's decision to sell 30,000 shares of Omega Healthcare Invts was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0000888491/000141588924022291//Archives/edgar/data/888491/000141588924022291/0001415889-24-022291-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $1,163,520.
Omega Healthcare Invts's shares are actively trading at $39.45, experiencing a up of 0.46% during Wednesday's morning session.
<h3>All You Need to Know About Omega Healthcare Invts</h3>
Omega Healthcare Investors Inc is a healthcare facility real estate investment trust that invests in the United States real estate markets. Omega's portfolio focuses on long-term healthcare facilities. Omega has one reportable segment consisting of investments in healthcare-related real estate properties located in the United States and the United Kingdom. Its core business is to provide financing and capital to the long-term healthcare industry with a particular focus on skilled nursing facilities (SNFs), assisted living facilities (ALFs), and to a lesser extent, independent living facilities (ILFs), rehabilitation and acute care facilities (specialty facilities) and medical office buildings (MOBs).
<h3>Omega Healthcare Invts: A Financial Overview</h3>
Revenue Growth: Over the 3 months period, Omega Healthcare Invts showcased positive performance, achieving a revenue growth rate of 1.02% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Real Estate sector.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company sets a benchmark with a high gross margin of 98.52%, reflecting superior cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Omega Healthcare Invts's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.46.
</li>
</ul>
Debt Management: Omega Healthcare Invts's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.26.
Valuation Overview:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 29.75 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: A higher-than-average P/S ratio of 10.36 suggests overvaluation in the eyes of investors, considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio 16.67 is below the industry average, indicating that it may be relatively undervalued compared to peers.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Understanding the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
When discussing legal matters, the term "insider" refers to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated in Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and significant hedge funds. Such insiders are required to report their transactions through a Form 4 filing, which must be completed within two business days of the transaction.
A new purchase by a company insider is a indication that they anticipate the stock will rise.
On the other hand, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Essential Transaction Codes Unveiled</h3>
Navigating through the landscape of transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, precisely detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0000888491">Check Out The Full List Of Omega Healthcare Invts's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Trades

Insider Transaction: ROBERT STEPHENSON Sells $1.16M Worth Of Omega Healthcare Invts Shares

A substantial insider sell was reported on August 27, by Megan Clarken, Chief Executive Officer at Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>), based on the recent SEC filing.
What Happened: Clarken's decision to sell 9,283 shares of Criteo was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001576427/000157642724000107//Archives/edgar/data/1576427/000157642724000107/0001576427-24-000107-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $456,445.
At Wednesday morning, Criteo shares are down by 0.42%, trading at $47.29.
<h3>All You Need to Know About Criteo</h3>
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
<h3>Criteo: Delving into Financials</h3>
Positive Revenue Trend: Examining Criteo's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 0.51% as of 30 June, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Communication Services sector.
Analyzing Profitability Metrics:
<ul>
<li>
Gross Margin: With a low gross margin of 49.4%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Criteo's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.49.
</li>
</ul>
Debt Management: Criteo's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 27.61 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.5 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry averages at 11.07, Criteo could be considered undervalued.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions are not the sole determinant of investment choices, but they are a factor worth considering.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>A Closer Look at Important Transaction Codes</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001576427">Check Out The Full List Of Criteo's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CRTO

Insider Transaction: Megan Clarken Sells $456K Worth Of Criteo Shares

Sarah Glickman, Chief Financial Officer at Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>), disclosed an insider sell on August 27, according to a recent SEC filing.
What Happened: Glickman opted to sell 1,519 shares of Criteo, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001576427/000157642724000108//Archives/edgar/data/1576427/000157642724000108/0001576427-24-000108-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $74,689.
Criteo's shares are actively trading at $47.0, experiencing a down of 1.03% during Wednesday's morning session.
<h3>All You Need to Know About Criteo</h3>
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
<h3>Criteo: Delving into Financials</h3>
Revenue Growth: Criteo displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 0.51%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Communication Services sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: With a low gross margin of 49.4%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Criteo's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 0.49.
</li>
</ul>
Debt Management: Criteo's debt-to-equity ratio is below the industry average at 0.1, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: The P/E ratio of 27.61 is lower than the industry average, implying a discounted valuation for Criteo's stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.5, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With an EV/EBITDA ratio lower than industry benchmarks at 11.07, Criteo presents an attractive value opportunity.
</li>
</ul>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Importance of Insider Transactions</h3>
Insider transactions, although significant, should be considered within the larger context of market analysis and trends.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
For <a href="https://www.benzinga.com/money/investing-tools">investors</a>, a primary focus lies on transactions occurring in the open market, as indicated in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001576427">Check Out The Full List Of Criteo's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Transaction: Sarah Glickman Sells $74K Worth Of Criteo Shares

Ryan Damon, Chief Legal Officer at Criteo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRTO#NASDAQ">CRTO</a>), disclosed an insider sell on August 27, according to a recent SEC filing.
What Happened: Damon's decision to sell 2,912 shares of Criteo was revealed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001576427/000157642724000109//Archives/edgar/data/1576427/000157642724000109/0001576427-24-000109-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value of the sale is $143,183.
Tracking the Wednesday's morning session, Criteo shares are trading at $47.0, showing a down of 1.03%.
<h3>About Criteo</h3>
Headquartered in Paris, Criteo is one of the leading ad-tech companies in the digital advertising market. Its technology, allows retailer advertisers to launch multichannel and cross-device marketing campaigns in real time. With real-time return on investment analysis of the ads, the firm's clients can adjust their marketing strategies dynamically. The firm also provides technology allowing retailers to effectively manage their ad inventories and improve yield optimization.
<h3>Understanding the Numbers: Criteo's Finances</h3>
Revenue Growth: Over the 3 months period, Criteo showcased positive performance, achieving a revenue growth rate of 0.51% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: With a low gross margin of 49.4%, the company exhibits below-average profitability, signaling potential struggles in cost efficiency compared to its industry peers.
</li>
<li>
Earnings per Share (EPS): Criteo's EPS outshines the industry average, indicating a strong bottom-line trend with a current EPS of 0.49.
</li>
</ul>
Debt Management: Criteo's debt-to-equity ratio is below the industry average. With a ratio of 0.1, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Analyzing Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 27.61 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The P/S ratio of 1.5 is lower than the industry average, implying a discounted valuation for Criteo's stock in relation to sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 11.07, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization: Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Navigating the Impact of Insider Transactions on Investments</h3>
While insider transactions provide valuable information, they should be part of a broader analysis in making investment decisions.
In the realm of legality, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities under Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are required to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
Notably, when a company insider makes a new purchase, it is considered an indicator of their positive expectations for the stock.
Conversely, insider sells may not necessarily signal a bearish stance on the stock and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
Surveying the realm of stock transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often give prominence to those unfolding in the open market, systematically detailed in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001576427">Check Out The Full List Of Criteo's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Criteo Chief Legal Officer Sold $143K In Company Stock

A substantial insider sell was reported on August 27, by David Fisher, Chief Executive Officer at Enova International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ENVA#NYSE">ENVA</a>), based on the recent SEC filing.
What Happened: After conducting a thorough analysis, Fisher sold 10,000 shares of Enova International. This information was disclosed in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001529864/000095017024101034//Archives/edgar/data/1529864/000095017024101034/0000950170-24-101034-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total transaction value is $844,496.
Enova International's shares are actively trading at $80.98, experiencing a down of 1.98% during Wednesday's morning session.
<h3>About Enova International</h3>
Enova International Inc provides online financial services, including short-term consumer loans, line of credit accounts, and installment loans to customers mainly in the United States and the United Kingdom. Consumers apply for credit online, receive a decision almost immediately, and can receive funds within one day. Enova acts as either the lender or a third-party facilitator between borrowers and other lenders. The company earns revenue from interest income, finance charges, and other fees, including fees on the transactions between borrowers and third-party lenders. The majority of revenue comes from the United States. The company realizes similar amounts of revenue from each of its three different products: short-term loans, lines of credit, and installment loans.
<h3>A Deep Dive into Enova International's Financials</h3>
Revenue Growth: Enova International displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 25.83%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Financials sector.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company shows a low gross margin of 47.62%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Enova International's EPS lags behind the industry average, indicating concerns and potential challenges with a current EPS of 2.0.
</li>
</ul>
Debt Management: Enova International's debt-to-equity ratio stands notably higher than the industry average, reaching 2.81. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 13.77 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: The current P/S ratio of 1.05 is below industry norms, suggesting potential undervaluation and presenting an investment opportunity for those considering sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): With a lower-than-industry-average EV/EBITDA ratio of 19.52, Enova International presents a potential value opportunity, as investors are paying less for each unit of EBITDA.
</li>
</ul>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
In the complex landscape of investment decisions, investors should approach insider transactions as part of a comprehensive analysis, considering various elements.
Within the legal framework, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as per Section 12 of the Securities Exchange Act of 1934. This includes executives in the c-suite and major hedge funds. These insiders are mandated to disclose their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
The initiation of a new purchase by a company insider serves as a strong indication that they expect the stock to rise.
However, insider sells may not always signal a bearish view and can be influenced by various factors.
<h3>Transaction Codes To Focus On</h3>
Taking a closer look at transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often prioritize those unfolding in the open market, meticulously cataloged in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C denotes the conversion of an option, and transaction code A signifies a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001529864">Check Out The Full List Of Enova International's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENVA

Chief Executive Officer Of Enova International Makes $844K Sale

Revealing a significant insider sell on August 27, John P Zimmer, EVP at Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>), as per the latest SEC filing.
What Happened: A Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001026655/000102665524000111//Archives/edgar/data/1026655/000102665524000111/0001026655-24-000111-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday outlined that Zimmer executed a sale of 15,653 shares of Core Molding Technologies with a total value of $287,099.
Core Molding Technologies's shares are actively trading at $17.89, experiencing a down of 2.03% during Wednesday's morning session.
<h3>Unveiling the Story Behind Core Molding Technologies</h3>
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
<h3>Core Molding Technologies's Economic Impact: An Analysis</h3>
Revenue Growth: Core Molding Technologies's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -9.19%. This indicates a decrease in the company's top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Navigating Financial Profits:
<ul>
<li>
Gross Margin: The company faces challenges with a low gross margin of 19.97%, suggesting potential difficulties in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Core Molding Technologies's EPS is below the industry average. The company faced challenges with a current EPS of 0.74. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Core Molding Technologies's debt-to-equity ratio is below the industry average at 0.15, reflecting a lower dependency on debt financing and a more conservative financial approach.
Valuation Metrics:
<ul>
<li>
Price to Earnings (P/E) Ratio: With a lower-than-average P/E ratio of 9.76, the stock indicates an attractive valuation, potentially presenting a buying opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.49 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 4.21, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Uncovering the Importance of Insider Activity</h3>
It's important to note that insider transactions alone should not dictate investment decisions, but they can provide valuable insights.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Transaction Codes Worth Your Attention</h3>
Examining transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> often concentrate on those unfolding in the open market, meticulously detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase, while S signifies a sale. Transaction code C indicates the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001026655">Check Out The Full List Of Core Molding Technologies's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Core Molding Technologies EVP Trades $287K In Company Stock

DAVID DUVALL, Chief Executive Officer at Core Molding Technologies (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CMT#AMEX">CMT</a>), executed a substantial insider sell on August 27, according to an SEC filing.
What Happened: DUVALL's recent move involves selling 20,000 shares of Core Molding Technologies. This information is documented in a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001026655/000102665524000113//Archives/edgar/data/1026655/000102665524000113/0001026655-24-000113-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The total value is $365,874.
The latest update on Wednesday morning shows Core Molding Technologies shares down by 2.03%, trading at $17.89.
<h3>Unveiling the Story Behind Core Molding Technologies</h3>
Core Molding Technologies Inc operates in the engineered materials market as one operating segment as a molder of thermoplastic and thermoset structural products. It produces and sells molded products for varied markets, including medium and heavy-duty trucks, automobiles, power sports, construction and agriculture, building products, and other industrial markets. The processes include compression molding of sheet molding compound (SMC), resin transfer molding (RTM), liquid molding of dicyclopentadiene (DCPD), spray-up and hand-lay-up, direct long-fiber thermoplastics (D-LFT) and structural foam, and structural web injection molding (SIM). It operates operates in Columbus, Ohio; Gaffney, South Carolina; Winona, Minnesota; Matamoros and Escobedo, Mexico; and Cobourg, Ontario, Canada.
<h3>Core Molding Technologies's Economic Impact: An Analysis</h3>
Revenue Challenges: Core Molding Technologies's revenue growth over 3 months faced difficulties. As of 30 June, 2024, the company experienced a decline of approximately -9.19%. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Key Profitability Indicators:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 19.97%, suggesting potential challenges in cost control and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Core Molding Technologies's EPS is below the industry average. The company faced challenges with a current EPS of 0.74. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.15.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The current P/E ratio of 9.76 is below industry norms, indicating potential undervaluation and presenting an investment opportunity.
</li>
<li>
Price to Sales (P/S) Ratio: With a P/S ratio of 0.49 below industry standards, the stock shows potential undervaluation, making it an appealing investment option for those focusing on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): The company's EV/EBITDA ratio of 4.21 trails industry averages, indicating a potential disparity in market valuation that could be advantageous for investors.
</li>
</ul>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Unmasking the Significance of Insider Transactions</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
In legal terms, an "insider" refers to any officer, director, or beneficial owner of more than ten percent of a company's equity securities registered under Section 12 of the Securities Exchange Act of 1934. This can include executives in the c-suite and large hedge funds. These insiders are required to let the public know of their transactions via a Form 4 filing, which must be filed within two business days of the transaction.
When a company insider makes a new purchase, that is an indication that they expect the stock to rise.
Insider sells, on the other hand, can be made for a variety of reasons, and may not necessarily mean that the seller thinks the stock will go down. 
<h3>Deciphering Transaction Codes in Insider Filings</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001026655">Check Out The Full List Of Core Molding Technologies's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Selling: DAVID DUVALL Unloads $365K Of Core Molding Technologies Stock

Making a noteworthy insider sell on August 27, Aaron Birnbaum, SVP &amp; Chief Operating Officer at Herc Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRI#NYSE">HRI</a>), is reported in the latest SEC filing.
What Happened: Birnbaum opted to sell 10,000 shares of Herc Hldgs, according to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001364479/000112760224022999//Archives/edgar/data/1364479/000112760224022999/0001127602-24-022999-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday. The transaction's total worth stands at $1,467,056.
The latest market snapshot at Wednesday morning reveals Herc Hldgs shares down by 0.0%, trading at $143.88.
<h3>Unveiling the Story Behind Herc Hldgs</h3>
Herc Holdings is an equipment rental company that was spun out of Hertz Global in 2016. It is currently the third-largest equipment rental company (4% market share) in North America, after United Rentals and Sunbelt Rentals, with a fleet size of $6.4 billion. It serves commercial and residential construction customers, the environmental sector, industrial entities, and entertainment production companies. During much of its 50-year-plus history, the company has rented equipment such as aerial lifts to its customers for intermittent use. More recently, it has broadened its catalog to include a host of specialty items. Separately, Herc Holdings' strategy now incorporates long-term rentals to industrial customers where Herc maintains its own staff at the customer site.
<h3>Herc Hldgs: Delving into Financials</h3>
Revenue Growth: Over the 3 months period, Herc Hldgs showcased positive performance, achieving a revenue growth rate of 5.74% as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Profitability Metrics: Unlocking Value
<ul>
<li>
Gross Margin: The company maintains a high gross margin of 36.08%, indicating strong cost management and profitability compared to its peers.
</li>
<li>
Earnings per Share (EPS): Herc Hldgs's EPS is notably higher than the industry average. The company achieved a positive bottom-line trend with a current EPS of 2.46.
</li>
</ul>
Debt Management: Herc Hldgs's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.53, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Market Valuation:
<ul>
<li>
Price to Earnings (P/E) Ratio: The Price to Earnings ratio of 12.08 is lower than the industry average, indicating potential undervaluation for the stock.
</li>
<li>
Price to Sales (P/S) Ratio: With a lower-than-average P/S ratio of 1.2, the stock presents an attractive valuation, potentially signaling a buying opportunity for investors interested in sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Indicated by a lower-than-industry-average EV/EBITDA ratio of 6.04, the company suggests a potential undervaluation, which might be advantageous for value-focused investors.
</li>
</ul>
Market Capitalization Analysis: Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>Why Insider Transactions Are Important</h3>
Insider transactions shouldn't be used primarily to make an investing decision, however, they can be an important factor for an investor to consider.
Exploring the legal landscape, an "insider" is defined as any officer, director, or beneficial owner holding more than ten percent of a company's equity securities, as stipulated by Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and major hedge funds. These insiders are required to report their transactions through a Form 4 filing, which must be submitted within two business days of the transaction.
Highlighted by a company insider's new purchase, there's a positive anticipation for the stock to rise.
But, insider sells may not necessarily indicate a bearish view and can be motivated by various factors.
<h3>Important Transaction Codes</h3>
When analyzing transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> tend to focus on those in the open market, detailed in Table I of the Form 4 filing. A P in Box 3 denotes a purchase,while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001364479">Check Out The Full List Of Herc Hldgs's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Insider Decision: Aaron Birnbaum Offloads $1.47M Worth Of Herc Hldgs Stock

Making a noteworthy insider sell on August 27, Michael Scott Rajeski, Chief Executive Officer at Latham Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWIM#NASDAQ">SWIM</a>), is reported in the latest SEC filing.
What Happened: According to a Form 4 filing with the <a href="https://www.sec.gov/Archives/edgar/data/0001833197/000141588924022325//Archives/edgar/data/1833197/000141588924022325/0001415889-24-022325-index.htm">U.S. Securities and Exchange Commission</a> on Tuesday, Rajeski sold 25,851 shares of Latham Group. The total transaction value is $169,065.
Monitoring the market, Latham Group's shares up by 1.63% at $6.25 during Wednesday's morning.
<h3>About Latham Group</h3>
Latham Group Inc is a designer, manufacturer, and marketer of in-ground residential swimming pools, liners, and covers in North America, Australia, and New Zealand. It derives a majority of its revenue from the United States.
<h3>Latham Group's Financial Performance</h3>
Decline in Revenue: Over the 3 months period, Latham Group faced challenges, resulting in a decline of approximately -9.6% in revenue growth as of 30 June, 2024. This signifies a reduction in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Insights into Profitability:
<ul>
<li>
Gross Margin: The company shows a low gross margin of 33.11%, indicating concerns regarding cost management and overall profitability relative to its industry counterparts.
</li>
<li>
Earnings per Share (EPS): Latham Group's EPS is below the industry average. The company faced challenges with a current EPS of 0.12. This suggests a potential decline in earnings.
</li>
</ul>
Debt Management: Latham Group's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.76, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
Valuation Analysis:
<ul>
<li>
Price to Earnings (P/E) Ratio: Latham Group's current Price to Earnings (P/E) ratio of 55.91 is higher than the industry average, indicating that the stock may be overvalued according to market sentiment.
</li>
<li>
Price to Sales (P/S) Ratio: With a relatively high Price to Sales ratio of 1.35 as compared to the industry average, the stock might be considered overvalued based on sales performance.
</li>
<li>
EV/EBITDA Analysis (Enterprise Value to its Earnings Before Interest, Taxes, Depreciation &amp; Amortization): Latham Group's EV/EBITDA ratio, surpassing industry averages at 12.91, positions it with an above-average valuation in the market.
</li>
</ul>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
<a href="https://www.schwab.com/brokerage?aff=XEC">Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm.</a>
<h3>The Impact of Insider Transactions on Investments</h3>
Insider transactions should be considered alongside other factors when making investment decisions, as they can offer important insights.
From a legal standpoint, the term "insider" pertains to any officer, director, or beneficial owner holding more than ten percent of a company's equity securities as outlined in Section 12 of the Securities Exchange Act of 1934. This encompasses executives in the c-suite and significant hedge funds. These insiders are mandated to inform the public of their transactions through a Form 4 filing, to be submitted within two business days of the transaction.
A company insider's new purchase is a indicator of their positive anticipation for a rise in the stock.
While insider sells may not necessarily reflect a bearish view and can be motivated by various factors.
<h3>Transaction Codes To Focus On</h3>
Delving into transactions, <a href="https://www.benzinga.com/money/investing-tools">investors</a> typically prioritize those unfolding in the open market, as precisely outlined in Table I of the Form 4 filing. A P in Box 3 indicates a purchase, while S signifies a sale. Transaction code C signals the conversion of an option, and transaction code A denotes a grant, award, or other acquisition of securities from the company.
<a href="https://www.benzinga.com/sec/insider-trades/search/index?company_cik=0001833197">Check Out The Full List Of Latham Group's Insider Trades.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SWIM

Insider Decision: Michael Scott Rajeski Offloads $169K Worth Of Latham Group Stock

AVAV

AeroVironment Awarded 5-Year $990M IDIQ Contract By U.S. Army For Lethal Unmanned Systems, Deliveries Of Switchblade Systems To Begin Soon

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The allure of <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares. And if the stock moves just a nickel or dime higher, you can make a killing that sets you up for life.



Unfortunately, that&rsquo;s not the way <a href="https://investorplace.com/2023/11/forget-penny-stocks-3-proven-winners-you-should-buy-instead/">most penny stocks work.</a> They are just as likely (if not more) to be pump-and-dump scams as they are real companies trying to make their way. Often they won&rsquo;t even have a product or service available. They are just a story, typically about whatever is hot at the moment.



Artificial intelligence (AI) is everywhere. So are companies claiming they will be the next Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>). Electric vehicles (EVs) seem to bring out all the lithium miners that will be a future Albemarle (NYSE:<a href="https://investorplace.com/stock-quotes/alb-stock-quote/">ALB</a>). And is gold climbing in value? Watch out for all the miners that spring to life. On second thought, gold-mining penny stocks are always around.



The truth is, if they are not trying to scam you, they are simply a business plan tucked inside a shell company looking to separate you from your money. There is a reason the SEC specifically <a href="https://www.sec.gov/investor/schedule15g.htm">warns about the risks</a> of investing in penny stocks.



While some low-priced stocks are viable businesses, it is so much easier to find winning investments by sticking with successful, profitable businesses with a proven track record of satisfying customers. The three stocks below are ones primed for multibagger returns.



<h2>JD.com (JD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/JD.com-stock-300x169.jpg" alt="JD stock, Jd.com, Tiger Global is a major investor in JD"><div>Source: Michael Vi / Shutterstock.com</div></div>Chinese online e-commerce platform JD.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/jd-stock-quote/">JD</a>) should head your list of stocks to buy. Shares are down 50% from their 52-week high, but this turnaround story has a long runway of future growth.&nbsp;



The online platform just turned in a strong fourth-quarter earnings report that easily beat analyst expectations. Although China&rsquo;s economy is slowing and consumer confidence is shaky, JD.com was able to drive tremendous traffic to its site via aggressive price cuts. While that eats into profits now, it will pay off later in customer loyalty. Operating margins fell 40 basis points (bp) from the year-ago figure but were better than the 60 bp decline Wall Street anticipated.



JD is following Amazon&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) game plan of dropping minimum order requirements for free delivery. Although that raised logistics costs, it also helped spur demand. It also reduced its commission fees in a bid to attract new merchants. All of this works against JD stock in the short term. It will pay big dividends for the Chinese e-commerce giant down the road. Coupled with a new $3 billion stock buyback program and JD.com is lining up for multibagger status very quickly.



<h2>PayPal (PYPL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/pypl1600-300x169.png" alt="Closeup of the PayPal app icon seen on a Google Pixel smartphone. PayPal Holdings, Inc. (PYPL) is a global financial technology company operating an online payment system."><div>Source: Tada Images / Shutterstock.com</div></div>Payments platform PayPal (NASDAQ:<a href="https://investorplace.com/stock-quotes/pypl-stock-quote/">PYPL</a>) also had a solid end-of-year report, though its outlook for 2024 was muted. PYPL stock is down 25% from recent highs but 17% above its lows. Long-term, though, Wall Street sees the company expanding earnings by 20% a year, well ahead of the 14% growth PayPal experienced over the past five years.



As an early leader in the payments space, PayPal has a competitive edge but faces growing competition on both the merchant and consumer side. Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>), Block (NYSE:<a href="https://investorplace.com/stock-quotes/sq-stock-quote/">SQ</a>) and Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) all intensified their own efforts at capturing the payments share. Apple Pay and Cash App are notable threats.



Still, PayPal holds an enviable presence in the online arena. The company is witnessing good traction with Braintree, its payments service provider. PayPal could also enhance its positioning in in-person transactions. Venmo remains a popular peer-to-peer transaction option, and PayPal is in the early stages of monetizing it.



PYPL stock may take a little longer to get going but should reward patient investors down the road.



<h2>Incyte (INCY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/incy-stock-1-300x169.jpg" alt="incy stock"><div>Source: Eyesonmilan / Shutterstock.com</div></div>Biotech Incyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/incy-stock-quote/">INCY</a>) is the dark horse candidate because the market doesn&rsquo;t recognize the value in its pipeline. Headline drugs like Jakafi for treating myelofibrosis and Opzelura for eczema are still big growth drivers.&nbsp;



In particular, Jakafi won&rsquo;t lose patent protection for another four years, although there are different myelofibrosis therapies on the market. Swedish Orphan Biovitrum&rsquo;s (OTCMKTS:<a href="https://investorplace.com/stock-quotes/swoby-stock-quote/">SWOBY</a>) Vonjo and GlaxoSmithKline&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>) Ojjaara have yet to hurt Jakafi sales, which <a href="https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2023-fourth-quarter-and-year-end-financial">came in</a> at $2.6 billion last year, an 8% increase. Incyte projects as much as $2.75 billion in sales in 2024.



Because the biotech has $3.65 billion in cash and equivalents available to it, the opportunity to pursue mergers and acquisitions as the Jakafi patent cliff approaches will intensify. Moreover, because Incyte can partner the therapy with other treatments in clinical trials it could stave off generic threats. It will enter a phase 3 trial later this year combining Jakafi with zilurgisertib, an ALK2 inhibitor. Other pairings could improve Jakafi&rsquo;s efficacy for already-approved indications.



The market might be distancing itself from INCY stock, but that gives savvy investors a chance to buy in at a better price on their way toward multibagger gains.



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>




<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT793992">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/02/wall-street-legend-issues-urgent-ai-code-red/?cid=MKT781156&amp;eid=MKT793990">&ldquo;America&rsquo;s Top Trader&rdquo; Issues A.I. Code Red: Act Now or Miss Out</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793999">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/penny-stock-detox-3-stocks-to-buy-for-multibagger-returns-instead/">Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The allure of <a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a> is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares. And if the stock moves just a nickel or dime higher, you can make a killing that sets you up for life.



Unfortunately, that&rsquo;s not the way <a href="https://investorplace.com/2023/11/forget-penny-stocks-3-proven-winners-you-should-buy-instead/">most penny stocks work.</a> They are just as likely (if not more) to be pump-and-dump scams as they are real companies trying to make their way. Often they won&rsquo;t even have a product or service available. They are just a story, typically about whatever is hot at the moment.



Artificial intelligence (AI) is everywhere. So are companies claiming they will be the next Nvidia (NASDAQ:<a href="https://investorplace.com/stock-quotes/nvda-stock-quote/">NVDA</a>). Electric vehicles (EVs) seem to bring out all the lithium miners that will be a future Albemarle (NYSE:<a href="https://investorplace.com/stock-quotes/alb-stock-quote/">ALB</a>). And is gold climbing in value? Watch out for all the miners that spring to life. On second thought, gold-mining penny stocks are always around.



The truth is, if they are not trying to scam you, they are simply a business plan tucked inside a shell company looking to separate you from your money. There is a reason the SEC specifically <a href="https://www.sec.gov/investor/schedule15g.htm">warns about the risks</a> of investing in penny stocks.



While some low-priced stocks are viable businesses, it is so much easier to find winning investments by sticking with successful, profitable businesses with a proven track record of satisfying customers. The three stocks below are ones primed for multibagger returns.



<h2>JD.com (JD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/08/JD.com-stock-300x169.jpg" alt="JD stock, Jd.com, Tiger Global is a major investor in JD"><div>Source: Michael Vi / Shutterstock.com</div></div>Chinese online e-commerce platform JD.com (NASDAQ:<a href="https://investorplace.com/stock-quotes/jd-stock-quote/">JD</a>) should head your list of stocks to buy. Shares are down 50% from their 52-week high, but this turnaround story has a long runway of future growth.&nbsp;



The online platform just turned in a strong fourth-quarter earnings report that easily beat analyst expectations. Although China&rsquo;s economy is slowing and consumer confidence is shaky, JD.com was able to drive tremendous traffic to its site via aggressive price cuts. While that eats into profits now, it will pay off later in customer loyalty. Operating margins fell 40 basis points (bp) from the year-ago figure but were better than the 60 bp decline Wall Street anticipated.



JD is following Amazon&rsquo;s (NASDAQ:<a href="https://investorplace.com/stock-quotes/amzn-stock-quote/">AMZN</a>) game plan of dropping minimum order requirements for free delivery. Although that raised logistics costs, it also helped spur demand. It also reduced its commission fees in a bid to attract new merchants. All of this works against JD stock in the short term. It will pay big dividends for the Chinese e-commerce giant down the road. Coupled with a new $3 billion stock buyback program and JD.com is lining up for multibagger status very quickly.



<h2>PayPal (PYPL)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2024/01/pypl1600-300x169.png" alt="Closeup of the PayPal app icon seen on a Google Pixel smartphone. PayPal Holdings, Inc. (PYPL) is a global financial technology company operating an online payment system."><div>Source: Tada Images / Shutterstock.com</div></div>Payments platform PayPal (NASDAQ:<a href="https://investorplace.com/stock-quotes/pypl-stock-quote/">PYPL</a>) also had a solid end-of-year report, though its outlook for 2024 was muted. PYPL stock is down 25% from recent highs but 17% above its lows. Long-term, though, Wall Street sees the company expanding earnings by 20% a year, well ahead of the 14% growth PayPal experienced over the past five years.



As an early leader in the payments space, PayPal has a competitive edge but faces growing competition on both the merchant and consumer side. Apple (NASDAQ:<a href="https://investorplace.com/stock-quotes/aapl-stock-quote/">AAPL</a>), Block (NYSE:<a href="https://investorplace.com/stock-quotes/sq-stock-quote/">SQ</a>) and Shopify (NYSE:<a href="https://investorplace.com/stock-quotes/shop-stock-quote/">SHOP</a>) all intensified their own efforts at capturing the payments share. Apple Pay and Cash App are notable threats.



Still, PayPal holds an enviable presence in the online arena. The company is witnessing good traction with Braintree, its payments service provider. PayPal could also enhance its positioning in in-person transactions. Venmo remains a popular peer-to-peer transaction option, and PayPal is in the early stages of monetizing it.



PYPL stock may take a little longer to get going but should reward patient investors down the road.



<h2>Incyte (INCY)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/incy-stock-1-300x169.jpg" alt="incy stock"><div>Source: Eyesonmilan / Shutterstock.com</div></div>Biotech Incyte (NASDAQ:<a href="https://investorplace.com/stock-quotes/incy-stock-quote/">INCY</a>) is the dark horse candidate because the market doesn&rsquo;t recognize the value in its pipeline. Headline drugs like Jakafi for treating myelofibrosis and Opzelura for eczema are still big growth drivers.&nbsp;



In particular, Jakafi won&rsquo;t lose patent protection for another four years, although there are different myelofibrosis therapies on the market. Swedish Orphan Biovitrum&rsquo;s (OTCMKTS:<a href="https://investorplace.com/stock-quotes/swoby-stock-quote/">SWOBY</a>) Vonjo and GlaxoSmithKline&rsquo;s (NYSE:<a href="https://investorplace.com/stock-quotes/gsk-stock-quote/">GSK</a>) Ojjaara have yet to hurt Jakafi sales, which <a href="https://investor.incyte.com/news-releases/news-release-details/incyte-reports-2023-fourth-quarter-and-year-end-financial">came in</a> at $2.6 billion last year, an 8% increase. Incyte projects as much as $2.75 billion in sales in 2024.



Because the biotech has $3.65 billion in cash and equivalents available to it, the opportunity to pursue mergers and acquisitions as the Jakafi patent cliff approaches will intensify. Moreover, because Incyte can partner the therapy with other treatments in clinical trials it could stave off generic threats. It will enter a phase 3 trial later this year combining Jakafi with zilurgisertib, an ALK2 inhibitor. Other pairings could improve Jakafi&rsquo;s efficacy for already-approved indications.



The market might be distancing itself from INCY stock, but that gives savvy investors a chance to buy in at a better price on their way toward multibagger gains.



On Penny Stocks and Low-Volume Stocks:&nbsp;With only the rarest exceptions,&nbsp;InvestorPlace does not publish commentary about companies that have a market cap of&nbsp;less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because&nbsp;these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market&nbsp;manipulators. If we ever do publish commentary on a low-volume stock that may be&nbsp;affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this&nbsp;fact and warn readers of the risks.



Read More:&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a>



On the date of publication, Rich Duprey did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guidelines.</a>




<div>Rich Duprey has written about stocks and investing for the past 20 years. His articles have appeared on Nasdaq.com, The Motley Fool, and Yahoo! Finance, and he has been referenced by U.S. and international publications, including MarketWatch, Financial Times, Forbes, Fast Company, USA Today, Milwaukee Journal Sentinel, Cheddar News, The Boston Globe, L&rsquo;Express, and numerous other news outlets.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/03/penny-stock-detox-3-stocks-to-buy-for-multibagger-returns-instead/">Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Swedish Orphan Biovitrum AB (publ) 2024 Q1 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q1 2024 Earnings Call Transcript

Swedish Orphan Biovitrum AB (publ) 2024 Q2 - Results - Earnings Call Presentation

Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript

AAPL

AMZN

INCY

PYPL

SHOP

Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (Sobi) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/SWOBY#OTC">SWOBY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BIOVF#OTC">BIOVF</a>)&nbsp;and Apellis Pharmaceuticals, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) on Thursday released topline data results from Phase 3 VALIANT study of systemic pegcetacoplan for C3 glomerulopathy (C3G) or primary immune complex membranoproliferative <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/n40248636/sobi-and-apellis-announce-positive-topline-results-from-phase-3-valiant-study-of-pegcetacoplan-in-" rel="noreferrer noopener">glomerulonephritis (IC-MPGN)</a>.



Excessive C3c deposits are a marker of disease activity, which can lead to kidney inflammation, damage, and failure. Additionally, two-thirds of patients who previously received a kidney transplant will experience disease recurrence. The diseases are estimated to affect 5,000 people in&nbsp;the U.S.&nbsp;and up to 8,000 in&nbsp;Europe.



The study met the primary endpoint, demonstrating a statistically significant and clinically meaningful 68% reduction in proteinuria in patients treated with pegcetacoplan compared to placebo, both in addition to background therapy, at Week 26.



Results were consistent across all subgroups, including C3G and IC-MPGN, adolescent and adult patients, and native and post-transplant kidneys.



Pegcetacoplan also demonstrated statistical significance on the key secondary endpoints of composite renal endpoint, which combines proteinuria reduction and estimated glomerular filtration rate (eGFR) stabilization, and proteinuria reduction of at least 50% compared to baseline, and nominal significance on the histological endpoint of reduction in C3c staining on kidney biopsy and stabilization of kidney function as measured by eGFR compared to placebo.



In the VALIANT study, pegcetacoplan showed favorable safety and tolerability, consistent with its established profile.



All patients who have completed the VALIANT study have enrolled in the VALE long-term extension study.



Sobi plans to submit a marketing application to the European Medicines Agency in 2025. Apellis also plans to submit a supplemental new drug application to the FDA in early 2025.



Pegcetacoplan is already approved in the U.S. for geographic atrophy secondary to age-related macular degeneration as Syfovre and paroxysmal nocturnal hemoglobinuria as Empaveli/Aspaveli.



Syfovre generated sales of $154.6 million, and Empaveli <a target="_blank" href="https://www.benzinga.com/pressreleases/24/08/g40095520/apellis-pharmaceuticals-reports-second-quarter-2024-financial-results" rel="noreferrer noopener">generated $24.5 million</a>.



In June, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a negative opinion on the marketing application of intravitreal pegcetacoplan for geographic atrophy.



Apellis plans to seek re-examination and expects a final opinion in the <a target="_blank" href="https://www.benzinga.com/pressreleases/24/06/g39544811/apellis-plans-to-seek-re-examination-following-negative-chmp-opinion-for-pegcetacoplan-for-geograp" rel="noreferrer noopener">fourth quarter of 2024</a>.



Price Action: APLS stock is up 11.2% at $37.35 at last check Thursday.



Photo via Shutterstock



Read Next:



<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/08/40251130/mounjaro-maker-eli-lillys-bumper-q2-earnings-exceeds-estimates-hikes-outlook-again-on-strong-diab" target="_blank" rel="noreferrer noopener">Mounjaro Maker Eli Lilly&#8217;s Bumper Q2 Earnings Exceeds Estimates, Hikes Outlook Again On Strong Diabetes And Weight Loss Drugs Sales</a>.</li>
</ul>

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Get Our Top Trade Ideas Delivered Daily - 65% Off Now'

Comments

Swedish Orphan Biovitrum

News

Latest news for Swedish Orphan Biovitrum (OTC:SWOBY) Stock

Thursday, August 08, 2024